Pancreatic Cancer Research

Clinical trialEarly Phase 1Withdrawn

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer

Outcome
Stopped earlyNo longer relevant to field (Other)
Phase
Early Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
15 October 2019
Planned end
6 December 2021
Enrollment
0 participants
Sites
2
Primary outcomes
To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.
Sponsor type
Industry
Results posted
No
Last update
11 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

This is a Phase 0 or "window of opportunity" study where paired specimen analysis, taken before and after drug exposure, will permit the evaluation of target modulation and assessment of immune effector cell infiltration into the tumor and the generation of relevant immune cytokines. In this study, BXCL701 will be administered at a dose of 0.3 mg, twice daily for a total daily dose of 0.6mg (the previously defined maximum tolerated dose \[MTD\] of the drug), to all patients for a short period of 14 days. This study is designed to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.